APM
DNLI icon

Avidity Partners Management’s Denali Therapeutics DNLI Stock Holding History

Avidity Partners Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-282,752
Closed -$8.34M – 91
2023
Q2 		$8.34M Buy
+282,752
New +$7.95M 0.29% 76
2021
Q3 		– Sell
-86,100
Closed -$6.75M – 114
2021
Q2 		$6.75M Buy
+86,100
New +$5.33M 0.18% 84

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Avidity Partners Management's DNLI Position: Q3 2023 in Review

Avidity Partners Management sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 282,752 shares — an estimated $8.34M sold.

Avidity Partners Management first reported a position in DNLI in Q2 2021 and held it in 2 quarters. The position peaked at $8.34M in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Avidity Partners Management reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Avidity Partners Management sold 282,752 Denali Therapeutics shares in Q3 2023, an estimated $8.34M.
  • Avidity Partners Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 2 quarters.
  • Avidity Partners Management's Denali Therapeutics position peaked at $8.34M in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.